


Megestrol acetate

Chemical Properties

CAS No. :	595-33-5
Formula:	C ₂₄ H ₃₂ O ₄
Molecular Weight:	384.51
Appearance:	no data available
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description

Description	Megestrol acetate (BDH1298) is a progestogen with actions and uses similar to those of the progestogens in general. Megestrol acetate also has anti-androgenic properties. It is given by mouth in the palliative treatment or as an adjunct to other therapy in endometrial carcinoma and in breast cancer. Megestrol acetate has been approved to treat anorexia and cachexia.
Targets(IC50)	Glucocorticoid Receptor, Estrogen/progestogen Receptor, Progesterone Receptor, HIV Protease, Autophagy
In vitro	Megestrol acetate inhibits the expression of cytoplasmic aromatase through nuclear C/EBPβ in reperfusion injury-induced ischemic rat hippocampus. [1] Megestrol acetate significantly increases the proliferation, migration, and adipogenic differentiation of adipose-derived stem cells (ASCs) in a dose-dependent manner. Megestrol acetate also upregulates genes downstream of glucocorticoid receptor (GR) in ASCs. [2]
In vivo	Megestrol acetate significantly decreases the circulating concentrations of estradiol (E2) and testosterone (T) in female fish or 11-ketotestosterone (11-KT) in male fish. Megestrol acetate exposure significantly downregulates the transcription of certain genes along the hypothalamic-pituitary-gonadal (HPG) axis. [3] Megestrol acetate produces a progressive deterioration in glucose tolerance, with a significant increase in mean fasting plasma glucose concentrations and decrease in mean plasma glucose clearance rates after 6 months and 12 months of treatment in cats. Megestrol acetate also produces a progressive decrease in both resting plasma cortisol concentrations and cortisol concentrations after ACTH stimulation in cats. [4] Megestrol acetate (50 mg/kg/day) for 9 days significantly increases food and water intake compared with untreated controls. Megestrol acetate (50 mg/kg/day) significantly (90-140%) increases in neuropeptide Y concentrations in the arcuate nucleus (where neuropeptide Y is synthesized), in the lateral hypothalamic area (through which arcuate neurones project) and in the medial preoptic area, ventromedial nucleus and dorsomedial nucleus in rats. [5]

Solubility Information

Solubility	Ethanol: 7.7 mg/mL (20 mM), DMSO: 19.2 mg/mL (50 mM), (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

A DRUG SCREENING EXPERT

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6007 mL	13.0036 mL	26.0071 mL
5 mM	0.5201 mL	2.6007 mL	5.2014 mL
10 mM	0.2601 mL	1.3004 mL	2.6007 mL
50 mM	0.052 mL	0.2601 mL	0.5201 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Kelicen Ugur P, et al. Eur J Pharmacol, 2011, 654(3), 217-225.

Sung JH, et al. Stem Cells Transl Med. 2015 Jul;4(7):789-99.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481